Vitamin a derivative combined with immunotherapy shows promise in early lung cancer trial
Disease control
Completed
This early-phase trial is testing a combination of all-trans retinoic acid (ATRA), a substance made from vitamin A, and the immunotherapy drug atezolizumab in people with advanced non-small cell lung cancer that has spread or come back. The main goal is to find the safest dose an…
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC